||Ramon V. Tiu, MD
Assistant Professor of Molecular Medicine, Department of Translational Hematology and Oncology Research
Taussig Cancer Institute
|Ramon Tiu works at Cleveland Clinic where he is well published in the area of single nucleotide polymorphism arrays, especially in their clinical application in myeloid malignancies like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). He received a young investigator award from the MDS Foundation and the Aplastic Anemia and MDS International Foundation and is a prior recipient of a T32 research award from Case Western Reserve University. He is involved in both clinical and translational research, focusing mainly on the field of myeloproliferative neoplasms and bone marrow failure syndromes. His research laboratory was one of the first groups to identify mutations in a gene called SF3B1 in MDS with ring sideroblasts, specifically refractory anemia with ring sideroblasts (RARS) and RARS associated with marked thrombocytosis (RARS-T). SF3B1 is a gene involved in an important physiologic post-transcriptional process called splicing. This is an unprecedented finding, as this is the first time that the spliceosome machinery has been implicated as a possible cause in blood cancers, particularly in MDS. Recently, his research laboratory found that ruxolitinib, a JAK1/2 inhibitor can improve pulmonary HTN in patients with myelofibrosis and that this may be mediated through improvement in serum/ plasma nitric oxide levels. He spearheads the MPN program of the Cleveland Clinic and is also very active in conducting clinical trials in bone marrow failure syndromes and myeloproliferative neoplasms (MPNs) and an active clinician seeing patients with MDS, MDS/MPN overlap syndromes, MPNs and rare bone marrow failure conditions. He is a member of the American Society of Hematology (ASH).
Medical Degree: University of Santo Tomas, Espana Manila, Philippines
Residency: Internal Medicine, Cleveland Clinic, Cleveland, Ohio
Fellowship: Bone Marrow Failure/ Experimental Hematology, Cleveland Clinic, Cleveland, Ohio
|Board Certification and Licensure
Medical License: Ohio
|Clinical and Research Interests
Myeloproliferative disorders/neoplasms myelodysplastic syndromes
Large granular lymphocyte leukemia
Paroxysmal nocturnal hemoglobinuria
Pure red cell aplasia
Chronic myelomonocytic leukemia (CMML)
1: Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, Arber D, Moore E, Morrissette JJ, Bagg A, Liu YC, Mathew S, Orazi A, Lin P, Wang SA, Bueso-Ramos CE, Foucar K, Hasserjian RP, Tiu RV, Karafa M, Hsi ED. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014 May; 99(5):821-9. doi: 10.3324/haematol.2013.096420. Epub 2014 Jan 24. PubMed PMID: 24463215.
2: Tabarroki A, Saunthararajah Y, Visconte V, Cinalli T, Colaluca K, Rogers HJ, Sekeres MA, Duong HK, Stein BL, Tiu RV. Ruxolitinib in combination with DNA methyltransferase inhibitors; clinical responses in symptomatic myelofibrosis patients with cytopenias and elevated blasts counts. Leuk Lymphoma. 2014 Apr 25. [Epub ahead of print] PubMed PMID: 24766471.
3: Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24;123(17):2645-51. doi: 10.1182/blood-2014-02-553800.
Epub 2014 Mar 13. PubMed PMID: 24627528.
4: Tiu RV, Sekeres MA. Making sense of the yelodysplastic/myeloproliferative neoplasms overlap syndromes. Curr Opin Hematol. 2014 Mar;21(2):131-40. doi: 10.1097/MOH.0000000000000021. PubMed PMID: 24378705.